Delafloxacin meglumine is primarily used as an antibiotic in the treatment of bacterial infections. It is indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by susceptible strains of bacteria. The medication works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. This makes it a valuable option for treating infections caused by both gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is often administered intravenously or orally, depending on the severity of the infection and patient needs. Its broad-spectrum activity and effectiveness against resistant strains make it a critical tool in managing complex skin infections and preventing complications.